{
  "id": 15605198,
  "title": "Top insider buys and sells disclosed on Friday",
  "url": "https://urgent.news/2026/10/19/top-insider-buys-and-sells-disclosed-on-friday",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-19T13:01:21.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/top-insider-buys-and-sells-disclosed-on-friday-93CH-4957491"
  },
  "original_language": "en",
  "account": "US-listed company Grace Therapeutics, Inc. experienced significant insider buying on Friday, October 16, 2026, according to disclosed trading activity. Opaleye Management Inc., a 10% owner and director of the company, purchased approximately 11,233 shares of GRCE at an average price of $1.9349 per share, up to a maximum of $1.98. This acquisition was made at a time when GRCE's stock was trading near its 52-week low of $1.79. Analysts have noted that GRCE appears undervalued, with price targets ranging from $3.92 to $7.88. Opaleye Management's purchase is seen as supportive of the company's prospects, as it currently trades at a low valuation amid positive analyst assessments.",
  "summary": null,
  "key_points": [
    "Opaleye Management Inc. bought 11,233 GRCE shares on Oct 16, 2026",
    "Purchase at $1.9349-$1.98 per share, up to 52-week low of $1.79",
    "Analysts view GRCE as undervalued with price targets $3.92-$7.88"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}